← Scoopfeeds — Intelligent news, curated.
GSK Agrees to Buy Nuvalent for $10.6 Billion
business

GSK Agrees to Buy Nuvalent for $10.6 Billion

Bloomberg Markets · Jun 9, 2026, 7:14 AM · Also reported by 2 other sources

GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that’s developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)

Read full story on Bloomberg Markets → More top stories

Also covered by

Investing.com UK’s GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion CNBC UK's GSK to acquire U.S. drugmaker Nuvalent for $10.6 billion as pharma giants race to expand pipelines

More in business

Bloomberg Markets
ECB 'At a Minimum' Is Going to Hike Twice: BNP Paribas (Video)
CNBC
UK's GSK to acquire U.S. drugmaker Nuvalent for $10.6 billion as pharma giants race to expand pipelines
CoinDesk
USDT's flashing a golden cross and that may be bad news for bitcoin
Investing.com
Morgan Stanley trims Saudi Arabia growth outlook as oil-sector contraction persists
MarketWatch
The latest rally may be only a dead-cat bounce, warns normally bullish boutique
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop